Eli Lilly Just Took a Hit - and That’s Exactly Why It’s Back on My Radar
LLY sold off after an FDA timing delay for its oral GLP-1, and the tape is now treating that as a bigger competitive loss to Novo than it likely is. With the stock sitting near its 10- and 50-day averages and momentum washed out, the setup favors a defined-risk long trade into a potential sentiment rebound and upcoming catalyst window.